Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03262584 · ClinicalTrials.gov registry record
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
A clinical trial of Invasive Fungal Infections and Immunocompromised, sponsored by Karius.
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT03262584: Completed study of Invasive Fungal Infections and Immunocompromised, sponsored by Karius.
NCT03262584 is a study of Invasive Fungal Infections and Immunocompromised that has completed, run by Karius. The registered enrollment target is 40 participants, roughly in line with the 42-participant average among 4 other Invasive Fungal Infections trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03262584, a study of Invasive Fungal Infections and Immunocompromised, has completed, sponsored by Karius.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The Sponsor hypothesize that Next-generation Sequencing (NGS) can identify fungal pathogens, is more accurate than other noninvasive options and can report fungal genomic load.
Primary Outcome
We aim to describe the incidence of positivity for fungal specific pathogens on NGS analysis in a high-risk immunocompromised pediatric population.
Conditions Studied
Study Locations (1)
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-05-17 |
| Est. Completion | 2018-09-28 |
What the finished NCT03262584 record still lists
NCT03262584 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, roughly in line with the 42-participant average among 4 other Invasive Fungal Infections trials with a reported enrollment target.
The record links to 4 conditions, with Invasive Fungal Infections appearing as the primary indexed condition, and to 0 interventions.
NCT03262584 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03262584 about?
NCT03262584 is a clinical study titled "Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients". The Sponsor hypothesize that Next-generation Sequencing (NGS) can identify fungal pathogens, is more accurate than other noninvasive options and can report fungal genomic load.
What is the current status of trial NCT03262584?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2017-05-17. Estimated completion is 2018-09-28.
What conditions does trial NCT03262584 study?
This clinical trial studies the following conditions: Invasive Fungal Infections, Immunocompromised, Invasive Fungal Disease, Fever and Neutropenia.
Who is sponsoring clinical trial NCT03262584?
This trial is sponsored by Karius, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03262584 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Fungal Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased Patients
COMPLETED
-
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
COMPLETED · Phase 3
-
Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
COMPLETED · Phase 2
-
A Bioequivalence Study of APX001 High-load and Low-load Tablets
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI